Hematological Oncology

期刊简介：Hematological Oncology considers for publication articles dealing with experimental and clinical aspects of neoplastic diseases of the hemopoietic and lymphoid systems and relevant related matters. Translational studies applying basic science to clinical issues are particularly welcomed. Manuscripts dealing with the following areas are encouraged:-Clinical practice and management of hematological neoplasia, including: acute and chronic leukemias, malignant lymphomas, myeloproliferative disorders-Diagnostic investigations, including imaging and laboratory assays-Epidemiology, pathology and pathobiology of hematological neoplasia of hematological diseases-Therapeutic issues including Phase 1, 2 or 3 trials as well as allogeneic and autologous stem cell transplantation studies-Aspects of the cell biology, molecular biology, molecular genetics and cytogenetics of normal or diseased hematopoeisis and lymphopoiesis, including stem cells and cytokines and other regulatory systems.Concise, topical review material is welcomed, especially if it makes new concepts and ideas accessible to a wider community. Proposals for review material may be discussed with the Editor-in-Chief. Collections of case material and case reports will be considered only if they have broader scientific or clinical relevance.

【译文】血液肿瘤学考虑发表关于造血和淋巴系统肿瘤的实验和临床方面的文章，以及相关相关事项。将基础科学应用于临床问题的转化研究特别受欢迎。鼓励以下领域的稿件：血液肿瘤的临床实践和管理，包括：急性白血病、慢性白血病、恶性淋巴瘤、骨髓增殖性疾病-诊断调查，包括影像学和实验室检测-血液肿瘤的流行病学、病理学和病理生物学-治疗问题，包括1期、2期或3期临床试验以及异基因和自体干细胞移植研究-正常或病态造血和淋巴生成的细胞生物学、分子生物学、分子遗传学和细胞遗传学方面，包括干细胞、细胞因子和其他调节系统。欢迎简明扼要的综述材料，特别是如果它使新的概念和思想对更广泛的社区变得可访问。综述材料的提案可以与主编讨论。只有当案例材料具有更广泛的科学或临床相关性时，才会考虑案例集和病例报告。